托业考试

【单选题】The legal dispute between Frecopy andDwean has yet to reach a conclusion. Talks between each side’s legal representatives have been ensuing for about a month now. They were close to a settlement about a week ago but have since slid back from their earlier talks due to new information that has been released by the FD
A、The FD
A、announced the discovery of a substance in both companys’ migraine medication mix that exceeds the daily recommended amount by 12%.
The major area of dispute is that Frecopy claims that they legally licensed the use of the main substances fromDwean to make the medication for minors; however, they claim they were unaware of the legal dosage required under the FD
A、regulations sinceDwean is the main applicant with the FD
A、However,Dwean claims Frecopy was fully aware of the legal dosage in talks prior to the actual licensing agreement signing.
Recently, analysts have downgraded both companies in their equity reports and say that the two companies should proceed with caution and do their best to work out a settlement with the FD
A、and each other quickly and quietly.Any long, dragged out, legal disputes with the FD
A、and the state prosecutor’s office could truly hurt both companies’ long-term profitability.
According to the report, what has caused the talks to take a step back
A、The disagreement over the name of their new product
B．The surfacing of new information
C．The lawyers on both sides not liking each other
D．The legality issue of the licensing process

网考网参考答案：B
网考网解析：
食品和药物监管局发表了有关两家企业生产的偏头痛药物成分的新结论。答案是(B)。 document.getElementById("warp").style.display="none"; document.getElementById("content").style.display="block"; 查看试题解析出处>>